HC Wainwright Reaffirms “Buy” Rating for UroGen Pharma (NASDAQ:URGN)

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reiterated by HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $64.00 target price on the stock.

Other analysts also recently issued research reports about the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Tuesday, February 18th. LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price objective for the company. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, UroGen Pharma presently has a consensus rating of “Buy” and a consensus price target of $40.00.

UroGen Pharma Trading Down 1.6 %

Shares of URGN stock opened at $9.36 on Tuesday. The stock has a market cap of $219.53 million, a P/E ratio of -2.97 and a beta of 1.08. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. UroGen Pharma has a fifty-two week low of $9.21 and a fifty-two week high of $20.70. The business has a fifty day simple moving average of $10.61 and a 200-day simple moving average of $12.03.

Insiders Place Their Bets

In other news, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the sale, the insider now owns 145,666 shares in the company, valued at $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares of the company’s stock, valued at approximately $294,853.52. This represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. KLP Kapitalforvaltning AS purchased a new stake in shares of UroGen Pharma during the 4th quarter valued at $59,000. Lazard Asset Management LLC purchased a new stake in UroGen Pharma during the fourth quarter valued at about $67,000. Aquatic Capital Management LLC acquired a new stake in UroGen Pharma during the fourth quarter worth about $101,000. China Universal Asset Management Co. Ltd. increased its stake in UroGen Pharma by 90.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after acquiring an additional 3,856 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after purchasing an additional 5,890 shares during the period. Institutional investors and hedge funds own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.